Form 4: Perspective Therapeutics Director Lori A. Woods Granted Stock Options

Director Lori A. Woods receives stock options as part of her annual equity award.

Summary

• Lori A. Woods, a director of Perspective Therapeutics, Inc., was granted stock options on March 3, 2025.
• The options allow her to purchase 50,000 shares of common stock at an exercise price of $2.46 per share.
• The options vest fully on March 3, 2026, contingent upon her continued service.
• The grant represents her annual equity award for 2025, approved by the Board of Directors on February 12, 2025.
• Woods has also granted power of attorney to Johan (Thijs) Spoor, Juan Graham, Jonathan Hunt and Chris Nenno to execute and file necessary SEC forms on her behalf.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a routine filing, so the sentiment is moderately positive.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The size of the grant (50,000 shares) and the vesting schedule (full vesting after one year) are within typical ranges for director equity awards, but would need to be compared to similar companies of similar size and stage of development to determine if it is above or below average.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their compensation strategy for directors and executives.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially driving long-term value creation.
• The vesting schedule incentivizes the director to remain engaged and contribute to the company's success.

Key Dates